Delivery Order SPE2DB20D1100-SPE2DB25FE3J2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 1,000 units of Duloxetine HCL DR 60 mg capsules, valued at $1,046.72. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,434.93 to AmerisourceBergen Drug Corp for 1,000 units of Duloxetine HCL DR 60 mg capsules, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a delivery order valued at $3,376.36 to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Duloxetine HCL DR 40 mg capsules (30-count units). This contract utilizes a firm fixed-price structure and is not set aside for any particular business category. The award is classified as a delivery order, indicating it derives from an existing indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Duloxetine HCL DR 60 mg capsules at a ceiling value of $1,433.94. This is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Duloxetine HCL DR 60 mg capsules (90-count) with a ceiling value of $2,267.82. The contract was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, and represents a non-set-aside, competitively awarded delivery order under firm fixed pricing. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order falls...
- The U.S. Defense Logistics Agency (DLA) awarded a $5,123.29 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of Duloxetine HCl DR 60 mg capsules. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999, which AmerisourceBergen holds with the DLA Troop Support Medical for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,674.67 firm fixed-price delivery order is for the supply of 4,564,690 units of Duloxetine HCL DR 40 mg capsules. The contract has an ultimate completion date of May 23, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,339.76, is a firm fixed-price delivery order for the supply of Duloxetine HCL DR 40 mg capsules. The contract has an ultimate completion date of December 18, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Duloxetine HCl DR 40 mg capsules. The contract has a ceiling value of $1,022.54 and a performance period extending through June 18, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $1,919.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 1,000 capsules of Duloxetine HCL DR 20 mg. This non-set-aside contract, which is due for completion by August 13, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate office location in...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE3J2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Duloxetine HCL DR 40 mg capsules (30-count packaging) with a ceiling value of $1,882.44. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of August 29, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion contract vehicle running through December 2026 that supports global pharmaceutical needs across the Department of Defense and federal healthcare systems. AmerisourceBergen Drug Corp, as a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a comprehensive range of pharmaceutical products across multiple therapeutic domains. As a child contract under the SPE2DX IDC, this delivery order exemplifies the ongoing procurement activities supporting the DLA's Medical Supply Chain mission to ensure pharmaceutical availability for military medical operations and federal healthcare beneficiaries worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/28/25 |